HeartSciences (HSCS) Change in Receivables (2022 - 2025)

HeartSciences (HSCS) posted quarterly Change in Receivables of -$4350.0 for Q3 2025, down 200.0% on a QoQ basis from $4350.0 in Q2 2025.

HeartSciences (HSCS) Change in Receivables (2022 - 2025) Analysis & Trends

HeartSciences (HSCS) has reported Change in Receivables for 3 consecutive years, with -$4350.0 the latest figure, recorded in Q3 2025.

Quarterly Change in Receivables changed N/A year-over-year to -$4350.0 in Q3 2025, while the trailing twelve-month figure through Oct 2025 was $10800.0 (changed N/A YoY) and the FY2026 annual result came in at -$4350.0, down 200.0% from the prior year.
Change in Receivables fell to -$4350.0 in Q3 2025 per HSCS's latest filing, from $4350.0 in the prior quarter.
Over the last five years, Change in Receivables for HSCS reached as high as $10800.0 in Q1 2024 and fell as low as -$4350.0 in Q3 2025.
A 3-year average of $2119.8 and a median of $1014.5 in 2022 frame the typical range for Change in Receivables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	42.00 Mn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-444.00 Mn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	287.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	117.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	117.90 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-124.60 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-141.00 Mn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	HeartSciences	2.29 Mn	-1.11 Mn	-	-

Download Data